Fig. 3From: Efficacy of active hexose correlated compound on survival of patients with resectable/borderline resectable pancreatic cancer: a study protocol for a double-blind randomized phase II studyTrial protocol. AHCC, active hexose correlated compound; NAT, neoadjuvant therapyBack to article page